ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Merck KGaA ramps up viral vaccine and gene therapy manufacturing

by Ryan Cross
April 24, 2020 | APPEARED IN VOLUME 98, ISSUE 16

 

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

09816-buscon15-gene.jpg
Credit: Merck KGaA
Merck is investing more than $100 million in virus manufacturing.

 

Merck KGaA is investing in the contract manufacturing of viruses used in viral vaccines, gene therapy, and engineered cell therapies. The firm will spend more than $100 million on a 13,000 m2 plant in Carlsbad, California, that will more than double the combined capacity of its existing facilities in Carlsbad and Glasgow, Scotland. The new site will be equipped to make viruses for clinical trials and commercial products. Merck recently said it will support large-scale manufacturing of a COVID-19 vaccine developed at the University of Oxford.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment